Early reinfarction after fibrinolysis: Experience from the global utilization of streptokinase and tissue plasminogen activator (Alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III) trials

Circulation

Volumn 104, Issue 11, 2001, Pages 1229-1235

  Hudson, Michael P ^a,g   Granger, Christopher B ^a   Topol, Eric J ^b   Pieper, Karen S ^a   Armstrong, Paul W ^c   Barbash, Gabriel I ^d   Guerci, Alan D ^e   Vahanian, Alec ^f   Califf, Robert M ^a   Ohman, E Magnus ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

^d TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^e ST FRANCIS HOSPITAL   (United States)

^f BICHAT HOSPITAL   (France)

^g HENRY FORD HOSPITAL   (United States)

Author keywords

Epidemiology; Fibrinolysis; Infarction; Mortality; Myocardial infarction; Trials

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOLYTIC AGENT; HEPARIN; NITRATE; RETEPLASE; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ADULT; AGE; AGED; ARTICLE; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; FEMALE; FIBRINOLYTIC THERAPY; GENDER; HEART RATE; HEART REINFARCTION; HEMODYNAMICS; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; POPULATION RESEARCH; PRIORITY JOURNAL; RISK FACTOR; SMOKING; ST SEGMENT ELEVATION; SYSTOLIC BLOOD PRESSURE; UNITED STATES;

EID: 0035845674     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/hc3601.095717     Document Type: Article

References (23)

1. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients
2. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
3. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction: Results from an international trial of 41 021 patients
4. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction
5. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: Results of the Thrombolysis In Myocardial Infarction (TIMI) phase II trial
6. GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction
7. ISIS-3: A randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction
8. A comparison of the early outcome of acute myocardial infarction in women and men
9. Frequency, significance and cost of recurrent ischemia after thrombolytic therapy for acute myocardial infarction
10. A comparison of reteplase with alteplase for acute myocardial infarction
11. Additive splines in statistics
12. One-year results from the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) Trial
13. Prognostic significance of nonfatal reinfarction during 3-year follow-up: Results of the Thrombolysis in Myocardial Infarction (TIMI) phase II clinical trial
14. Identification of high-risk patients with silent myocardial ischemia after percutaneous transluminal coronary angioplasty by multilead monitoring
15. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin
16. Recurrent ischemia after thrombolysis: Importance of associated clinical findings
17. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction
18. Reactivation of ischemic events in acute coronary syndromes: Results from GUSTO-IIb
19. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: Results from the GUSTO-I trial
20. Evaluation of the paradoxical beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: Mechanism of the "smoker's paradox" from the GUSTO-I trial, with angiographic insights
21. Reinfarction after thrombolytic therapy for acute myocardial infarction followed by conservative management: Incidence and effect of smoking
22. Significance of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: Experience gleaned from the International Tissue Plasminogen Activator/Streptokinase Mortality Trial
23. Treatment of reinfarction after thrombolytic therapy for acute myocardial infarction: An analysis of outcome and treatment choices in the Global Utilization of Streptokinase and Tissue plasminogen activator for Occluded coronary arteries (GUSTO I) and Assessment of the safety of a New Thrombolytic (ASSENT 2) studies